Literature DB >> 8187985

Elevated serum CA19-9 levels in poorly controlled diabetic patients. Relationship with Lewis blood group.

J M Petit1, G Vaillant, N O Olsson, F Guignier, S Collignon, B Verges, J M Brun.   

Abstract

Many non-malignant diseases may be associated with elevated serum CA19-9 levels. Recent reports suggest that diabetes mellitus may also be responsible for some elevations. In this study we investigated the influence of the glycaemic level and Lewis phenotype on the serum CA19-9 levels in diabetic patients. In 15 out of 84 patients (17.8%) serum CA19-9 exceeded 100 kU/L (highest value: 208 kU/L). CA19-9 concentrations were significantly correlated with glycosylated haemoglobin levels. On the other hand, no correlation was found between CA19-9 levels and the type of diabetes, lipase levels, or the presence of anti-islet cell antibodies. Le(a-b-) patients had significantly lower serum CA19-9 levels. This study emphasizes the frequency of CA19-9 elevations in diabetic patients without cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8187985

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  8 in total

1.  A new cause for CA19.9 elevation: heavy tea consumption.

Authors:  M Howaizi; M Abboura; C Krespine; M-S Sbai-Idrissi; O Marty; M Djabbari-Sobhani
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

2.  Clinical implication of elevated CA 19-9 level and the relationship with glucose control state in patients with type 2 diabetes.

Authors:  Sun Hee Kim; Cho-Ok Baek; Kyung Ae Lee; Tae Sun Park; Hong Sun Baek; Heung Yong Jin
Journal:  Endocrine       Date:  2013-10-10       Impact factor: 3.633

3.  Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes.

Authors:  Qingqu Guo; Muxing Kang; Bo Zhang; Ying Chen; Xin Dong; Yulian Wu
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-20       Impact factor: 4.553

4.  Serum CA19-9 level associated with metabolic control and pancreatic beta cell function in diabetic patients.

Authors:  Haoyong Yu; Ruixia Li; Lei Zhang; Haibing Chen; Yuqian Bao; Weiping Jia
Journal:  Exp Diabetes Res       Date:  2012-06-12

5.  Decreased serum CA19-9 is associated with improvement of insulin resistance and metabolic control in patients with obesity and type 2 diabetes after Roux-en-Y gastric bypass.

Authors:  Yinfang Tu; Haoyong Yu; Pin Zhang; Jianzhong Di; Xiaodong Han; Songhua Wu; Yuqian Bao; Weiping Jia
Journal:  J Diabetes Investig       Date:  2014-02-26       Impact factor: 4.232

6.  Delayed radiation-induced inflammation accompanying a marked carbohydrate antigen 19-9 elevation in a patient with resected pancreatic cancer.

Authors:  Malcolm D Mattes; Jon S Cardinal; Geraldine M Jacobson
Journal:  Radiat Oncol J       Date:  2016-06-17

7.  Synergistic Association of Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 on the Risk of Abnormal Glucose Regulation.

Authors:  Yu-Cheng Cheng; Yu-Hsuan Li; Chiann-Yi Hsu; I-Te Lee
Journal:  Diabetes Metab Syndr Obes       Date:  2020-06-10       Impact factor: 3.168

8.  Association between cancer antigen 19-9 and diabetes risk: A prospective and Mendelian randomization study.

Authors:  Zhaoyang Li; Jing Wang; Xu Han; Fei Wang; Hua Hu; Jing Yuan; Ping Yao; Sheng Wei; Huan Guo; Dan Zheng; Yuhan Tang; Handong Yang; Meian He
Journal:  J Diabetes Investig       Date:  2019-11-28       Impact factor: 4.232

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.